Modeling drug mechanism knowledge using evidence and truth maintenance

IEEE Transactions on Information Technology in Biomedicine

Volumn 11, Issue 4, 2007, Pages 386-397

  Boyce, Richard D ^a   Collins, Carol ^a   Horn, John ^a   Kalet, Ira ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug interactions; Drug mechanisms; Knowledge representation; Truth Maintenance Systems

Indexed keywords

DRUG INTERACTION KNOWLEDGE-BASE (DIKB); DRUG MECHANISMS; METABOLIC MECHANISMS; TRUTH MAINTENANCE SYSTEMS;

BIOINFORMATICS; KNOWLEDGE BASED SYSTEMS; KNOWLEDGE REPRESENTATION; METABOLISM;

DRUG INTERACTIONS;

ARTICLE; ARTIFICIAL INTELLIGENCE; DRUG INTERACTION; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; MEDICAL INFORMATICS; METHODOLOGY; NATURAL LANGUAGE PROCESSING; STATISTICAL MODEL;

ARTIFICIAL INTELLIGENCE; DATABASES, FACTUAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; LOGISTIC MODELS; MEDICAL INFORMATICS; NATURAL LANGUAGE PROCESSING;

EID: 34547135453     PISSN: 10897771     EISSN: None     Source Type: Journal    
DOI: 10.1109/TITB.2007.890842     Document Type: Article

References (30)

1. H. Derendorf, L. Lesko, P. Chaikin,W. Colburn, P. Lee, R. Miller, R. Powell, G. Rhodes, D. Stanski, and J. Venitz, "Pharmacokinetic/ pharmacodynamic modeling in drug research and development," J. Clin. Pharmacol., vol. 40, pp. 1399-1418, 2000.
2. F. Yamashita and M. Hashida, "In silico approaches for predicting ADME properties of drugs," Drug Metab. Phamacokin., vol. 19, no. 5, pp. 327-338, 2004.
3. H. van de Waterbeemd and E. Gifford, "ADMET in silico modlling: Towards prediction paradise," Nat. Rev., vol. 2, pp. 192-204, Mar. 2003.
4. R. S. Obach, R. L. Walsky, K. Venkatakrishnan, J. B. Houston, and L. Tremaine, "In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach," Clin. Pharmacol. Ther. vol. 78, pp. 582-92, 2005.
5. P. Hansten, "Drug interaction management," Pharm. World Sci., vol. 25, no. 3, pp. 94-97, Jun. 2003.
6. Internal. (Sep. 25, 2006). FDA guideline: Drug interaction studies - Study design, data analysis, and implication for dosing and labeling. Online. Available: http://www.fda.gov/Cber/gdlns/interactstud.htm
7. P. D. Hansten and J. R. Horn, "Cytochrome P450 enzymes and drug interactions," The Top 100 Drug Iteractions, A Guide to Patient Management. Freeland, WA: H&H Publications, 2004.
8. C. Collins and R. Levy, "Drug-drug interaction in the elderly with epilepsy: Focus on antiepileptic, psychiatric, and cardiovascular drugs," Profiles Seizure Manage., vol. 3, no. 6, 2004.
9. R. Boyce, C. Collins, J. Horn, and I. Kalet, "Qualitative pharmacokinetic modeling of drugs," in Proc. AMIA, 2005, pp. 71-75.
10. Accolate Zafirlukast Tablets, AstraZeneca, London, U.K., product label, Jul. 2004
11. J. H. Lin, "Sense and nonsense in the prediction of drug-drug interactions," Current Drug Metab., vol. 1, no. 4, pp. 305-332, 2000.
12. K. Ito, H. S. Brown, and J. B. Houston, "Database analysis for the prediction of in vivo drug drug interactions from in vitro data," Br. J. Clin. Pharmacol., vol. 57, no. 4, pp. 473-486, 2003.
13. X. Wen, J.Wang, J. Backman, K. Kivisto, and P. Neuvonen, "Gemfibrozil is a potent inhibitor of human Cytochrome-P4502C9," Drug Metab. Dispos. vol. 29, no. 11, pp. 1359-1361, Nov. 2001.
14. J. Rindone and H. Keng, "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia," Chest, vol. 114, no. 2, pp. 641-642, Aug. 1998.
15. I. Kapetanovic and H. Kupferberg, "Stable isotope methodology and gas chromatography mass spectrometry in a pharmacokinetic study of phenobarbital," Biomed. Mass Spectrom., vol. 7, no. 2, pp. 47-52, 1980.
16. I. Kapetanovic, H. Kupferberg, R. Porter,W. Theodore, E. Schulman, and J. Penry, "Mechanism of valproate-phenobarbital interaction in epileptic patients," Clin. Pharmacol. Ther., vol. 29, no. 4, pp. 480-486, Apr. 1981.
17. X. Wen, J. Wang, K. Kivisto, P. Neuvonen, and J. Backman, "In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P450 2C9 (CYP2C9)," Br. J. Clin. Pharmacol., vol. 52, no. 5, pp. 547-53, 2001.
18. A. Bundy, "Incidence calculus," Univ. Edinburgh, Edinburgh, U.K., DAI Res. paper, Apr. 2004, (commisioned by the Encyclopedia of Artificial Intelligence).
19. J. Pearl and S. Russell, "Bayesian networks," UCLA Cogn. Syst. Lab., Los Angeles, CA, Tech. Rep., Nov. 2000.
20. R. Davis, B. Buchanan, and E. Shortliffe, "Production rules as a basis for a knowledge-based consultation program," Artif. Intell., vol. 8, no. 1, pp. 15-45, 1977.
21. S. Parsons and A. Hunter. (1998). A review of uncertainty handling formalisms. Applications of Uncertainty Formalisms Online. pp. 8-37, Available: Citeseer.ist.psu.edu/parsons98review.htmlx
22. S. Russel and P. Norvig, "Probabilistic reasoning," in Artificial Intelligence: A Modern Approach. Englewood Cliffs, NJ: Prentice-Hall, 2003.
23. P. Bonnabry, J. Sievering, T. Leemann, and P. Dayer, "Quantitative drug interactions prediction system (Q-DIPS): A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies," Clin. Pharmacokinet., vol. 40, no. 9, pp. 631-640, 2001.
24. D. Griffin and L. Brenner, "Perspectives on probability judgment," in The Blackwell Handbook of Judgement and Decision Making. Oxford, U.K.: Blackwell, 2004.
25. M. Goldszmidt and J. Pearl, "Qualitative probabilities for default reasoning, belief revision, and causal modeling," Artif. Intell., vol. 84, pp. 57-112, 1996.
26. K. D. Forbus and J. De. Kleer, Building Problem Solvers. Cambridge, MA: MIT Press, 1993.
27. P. Marroum and J. Gobburu, "The product label: How pharmacokinetics and pharmacodynamics reach the prescriber,," Clin. Pharmacokinet, vol. 41, no. 3, pp. 161-169, 2002.
28. D. Williams and J. Feely, "Pharmacokinetic-Pharmacodynamic drug interactions with HMG-CoA reductase inhibitors," Clin. Phamacokinet. vol. 41, no. 5, pp. 343-370, 2002.
29. K. E. Thummel, K. L. Kunze, and D. D. Shen, "Metabolically-based drug-Drug interactions: Principles and mechanisms," in Metabolic Drug Interactions, R. H. Levy, K. E. Thummel,W. F. Trager, P. D. Hansten, and M. Eichelbaum, Eds. Baltimore, MD: Williams & Wilkins, 2000.
30. P. Karp, S. Paley, C. Krieger, and P. Zhang, "An evidence ontology for use in pathway/genome databases," in Proc. Pac. Symp. Biocomput., 2004, pp. 190-201.